Evidence map›Paper›PMID 41321907›Full record

ReviewMayo Clinic proceedings. Innovations, quality & outcomes2025

A Systematic Literature Review of Coordinated Care in Cardiovascular-Kidney-Metabolic Conditions.

O Kenrik Duru, Radica Alicic, Muthiah Vaduganathan, Wendy L St Peter, Glenda V Roberts, Janani Rangaswami, Susanne B Nicholas, Joshua J Neumiller, Roy O Mathew, Patrick Gee and 1 more

Abstract readReview
In one paragraph

Review in Mayo Clinic proceedings. Innovations, quality & outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

O Kenrik DuruDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine, Los Angeles, CA.
Radica AlicicProvidence Medical Research Center, Providence Inland Northwest Health, Spokane, WA.
Muthiah VaduganathanBrigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA.
Wendy L St PeterDepartment of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN.
Glenda V RobertsBarbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York City, NY.
Janani RangaswamiDivision of Nephrology, Washington DC VA Medical Center, Washington, DC.
Susanne B NicholasDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA.
Joshua J NeumillerDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA.
Roy O MathewLoma Linda VA Health Care System, Loma Linda, CA.
Patrick GeeiAdvocate Inc, P Gee Consulting, LLC, Greater Richmond Region, VA.
Katherine R TuttleProvidence Medical Research Center, Providence Inland Northwest Health, Spokane, WA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess coordinated cardiovascular-kidney-metabolic (CKM) care programs, including program types, components, and outcomes. Patients and Methods: We searched Embase and Medline for studies from January 1, 2015 through March 9, 2023, and congress abstracts from January 1, 2021 through March 9, 2023. For inclusion, patients were required to have ≥2 CKM conditions and the coordinated care program assessed the effectiveness of either treatment, monitoring, or risk reduction of all 3 conditions. Two reviewers extracted and assessed the data for accuracy. Randomized controlled trials were assessed for potential bias in the design, conduct, and reporting of clinical trials risk of bias using the Cochrane risk of bias tool, version 2. Observational studies were assessed using the Newcastle-Ottawa Scale. Results: A total of 22 international studies met our inclusion criteria; interventions included patient visits to multidisciplinary team (MDT) care clinics (n=9), pharmacist integration (n=5), patient engagement and education (n=6), or MDT/multispecialty team meetings (n=2). The sample size of studies ranged from 14 to 9601. Overall, results showed greater patient satisfaction and fewer health-related problems with coordinated care programs versus usual care, with increased attendance rates and decreased health care costs for virtual consultations, and further reductions for programs integrating telehealth. Conclusion: Coordinated care for patients with CKM conditions may improve clinical outcomes and reduce healthcare costs. Future research is needed to develop programs with standard reporting, to assess overall effectiveness, and to identify best practices for implementing coordinated care programs. Limitations included heterogeneity in the interventions' design, delivery, CKM population, and outcomes assessed. Trial Registration: PROSPERO Identifier: CRD42023409731.

Identifiers

PMID41321907
PMCPMC12657295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.